Although HER2-targeted agents can inhibit the HER2 expression in tumor cells, the HER2-independent escape mechanisms, such as the constitutive activation of PI3K/AKT pathway, might lead to a less sensitive tumor phenotype [26, 27]. The gene discussed is ERBB2; the disease is neoplasm.